New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on February 27, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EVP Nimrata Hunt of Idexx Laboratories has executed a notable insider transaction, selling 2,693 shares of the company’s stock in a deal valued at $1,781,527, signaling a sizeable move within the firm’s executive ranks.
Recent Updates on IDXX stock
Idexx Laboratories’ shares reacted to a Q4 beat and upbeat 2026 outlook, as revenue and EPS topped expectations and management highlighted double‑digit organic growth, record premium instrument placements, expanding margins, and strong cash generation. Analysts’ target revisions were driven mainly by confidence in recurring CAG diagnostics, the traction of new platforms like inVue DX and CancerDx, growing software/SaaS revenue, and guidance that balances higher capex and tougher U.S. clinic trends with sustained pricing power and international growth.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
The score is anchored by strong financial quality (premium margins, solid free cash flow, and improved balance sheet) and supportive 2026 guidance. Offsetting factors are weak current technical momentum and a high P/E that leaves less room for error, with corporate execution risk around the CEO transition as a secondary consideration.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
YTD Price Performance: -2.83%
Average Trading Volume: 509,343
Technical Sentiment Signal: Buy
Current Market Cap: $51.69B